Download PDF
Thromb Haemost 1995; 74(06): 1564-1572
DOI: 10.1055/s-0038-1649983
Original Articles
platelets
Schattauer GmbH Stuttgart

On the Role of Platelet FcγRIIa Phenotype in Heparin-Induced Thrombocytopenia

John T Brandt
1   The Department of Pathology, The Ohio State University, Columbus, Ohio, USA
,
Craig E Isenhart
1   The Department of Pathology, The Ohio State University, Columbus, Ohio, USA
,
Jeanne M Osborne
2   The Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA
,
Alaa Ahmed
2   The Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA
,
Clark L Anderson
2   The Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA
› Author Affiliations
Further Information

Publication History

Received 20 April 1995

Accepted after resubmission 16 August 1995

Publication Date:
10 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Heparin induced thrombocytopenia (HIT) is characterized by the formation of antibodies that activate normal donor platelets in vitro in the presence of heparin. We asked whether the commonly observed donor-specific variation in the platelet aggregation response to HIT antibodies is influenced by the density of FcγRII on platelets or by the Arg/His 131 allelic polymorphism of platelet FcγRII. We found that platelets with the His/Hisl31 FcγRII phenotype were unresponsive to HIT antibody (0/9) whereas platelets with the Arg/Argl31 phenotype responded well (7/9). His/Hisl31 platelets were largely unresponsive also to a murine IgG1 antiplatelet monoclonal antibody (UR1) known to activate platelets by FcγRII clustering. We then determined the frequency distribution of FcγRIIa Arg/His 131 phenotypes on a series of 200 patients evaluated for HIT and 100 non-thrombocytopenic hospitalized patients. The frequency of the His/Hisl31 phenotype was significantly increased (34.4%) in the 96 thrombocytopenic patients with HIT antibody compared to the 104 thrombocytopenic patients without HIT antibody and the 100 non-thrombocytopenic patients (∼19%). Thus, the FcγRII phenotype regulates the in vitro activation response of normal platelets to HIT antibody and is a risk factor for the thrombocytopenia of HIT

 

  • References

  • 1 Ansell J, Deykin D. Heparin-induccd thrombocytopenia and recurrent thromboembolism. Am J Hematol 1980; 8: 325-332
    CrossrefPubMedGoogle Scholar
  • 2 Warkentin TE, Kelton JG. Heparin-induced thrombocytopenia. In: Progress in Hemostasis and Thrombosis Vol 10. Coller BS. (ed) Philadelphia: W. B. Saunders; 1991. pp 1-34
    Google Scholar
  • 3 Chong BH. Heparin-induced thrombocytopenia. Aust NZ J Med 1992; 22: 145-152
    CrossrefPubMedGoogle Scholar
  • 4 Kelton JG, Sheridan D, Santos A, Smith J, Steeves K, Smith C, Brown C, Murphy WG. Heparin-induced thrombocytopenia: laboratory studies. Blood 1988; 72: 925-930
    CrossrefPubMedGoogle Scholar
  • 5 Chong BH, Castaldi PA, Berndt MC. Heparin-induced thrombocytopenia: effects of rabbit IgG, and its Fab and Fc fragments on antibody-heparin-platelet interaction. Thromb Res 1989; 55: 291-295
    CrossrefPubMedGoogle Scholar
  • 6 Chong BH, Ismail F, Chesterman CN, Berndt MC. Heparin-induced thrombocytopenia: mechanism of interaction of the heparin-dependent antibody with platelets. Br J Haematol 1989; 73: 235-240
    CrossrefPubMedGoogle Scholar
  • 7 Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986; 67: 27-30
    Google Scholar
  • 8 Babcock RB, Dumper CW, Scharfman WB. Heparin-induced immune thrombocytopenia. N Engl J Med 1976; 295: 237-241
    CrossrefPubMedGoogle Scholar
  • 9 Fratantoni JC, Pollet R, Gralnick HR. Heparin-induced thrombocytopenia: confirmation of diagnosis with in vitro methods. Blood 1975; 45: 395-401
    PubMedGoogle Scholar
  • 10 Salem HH, van der Weyden MB. Heparin induced thrombocytopenia. Variable platelet-rich plasma reactivity to heparin dependent aggregating factor Pathology 1983; 15: 297-299
    CrossrefPubMedGoogle Scholar
  • 11 Kelton JG, Sheridan D, Brain H, Powers PJ, Turpie AG, Carter CJ. Clinical usefulness of testing for a heparin-dependent platelet aggregating factor on patients with suspected heparin-associated thrombocytopenia. J Lab Clin Med 1984; 103: 606-612
    PubMedGoogle Scholar
  • 12 Warkentin TE, Hayward CP M, Smith CA, Kelly PM, Kelton JG. Determinants of donor variability when testing for heparin-induced thrombocytopenia. J Lab Clin Med 1992; 120: 371-379
    Google Scholar
  • 13 Gruel Y, Rupin A, Darnige L, Moalic-Reverdiau P, Poumier-Gaschard P, Binet C, Bardos P, Leroy J. Specific quantification of heparin-dependent antibodies for the diagnosis of heparin-associated thrombocytopenia using an enzyme-linked immunosorbent assay. Thromb Res 1991; 62: 377-387
    CrossrefPubMedGoogle Scholar
  • 14 Chong BH, Burgess J, Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost 1993; 69: 344-350
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Isenhart CE, Brandt JT. Platelet aggregation studies for the diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol 1993; 99: 324-330
    CrossrefPubMedGoogle Scholar
  • 16 Greinacher A, Mueller-Eckhardt G. Heparin-associated thrombocytopenia: no association of immune response with HLA. Vox Sang 1993; 65: 151-153
    PubMedGoogle Scholar
  • 17 van de Winkle JG J, Anderson CL. Biology of human immunoglobulin G Fc receptors. J Leukocyte Biol 1991; 49: 511-524
    CrossrefPubMedGoogle Scholar
  • 18 Warmerdam PA M, van de Winkel JG J, Gosselin EJ, Capel PJ A. Molecular basis for a polymorphism of human Fcγ receptor II (CD32). J Exp Med 1990; 172: 19-25
    CrossrefPubMedGoogle Scholar
  • 19 Clark MR, Stuart SG, Kimberly RP, Ory PA, Goldstein IM. A single amino acid distinguishes the high-responder from the low-responder form of Fc receptor II on human monocytes. Eur J Immunol 1991; 21: 1911-1916
    CrossrefPubMedGoogle Scholar
  • 20 Warmerdam PA M, van de Winkel JG J, Vlug A, Westerdaal NA C, Capel PJ A. A single amino acid in the second Ig-like domain of the human Fcγ receptor II is critical for human IgG2binding. J Immunol 1991; 147: 1338-1343
    PubMedGoogle Scholar
  • 21 Tax WJ M, Willems HW, Reekcrs PP M, Capel PJ A, Koene RA P. Polymorphism in mitogenic effect of IgG, monoclonal antibodies against T3 antigen on human T cells. Nature 1983; 304: 445-447
    CrossrefPubMedGoogle Scholar
  • 22 Tax WJ M, Hermus FF M, Willems II W, Cappel PJ A, Koene RA P. Fc receptors for mouse IgG, on human monocytes: polymorphism and role in antibody-induced T cell proliferation. J Immunol 1984; 133: 1185-1189
    PubMedGoogle Scholar
  • 23 van de Winkel JG J, Fax WJ M, van Bruggen MC J, van Roozendaal CE P, Willems HW, Vlug A, Capel PJ A, Koene RA P. Characterization of two Fc receptors for mouse immunoglobulins on human monocytes and cell lines. Scand J Immunol 1987; 26: 663-672
    CrossrefPubMedGoogle Scholar
  • 24 Anderson CL, Ryan DH, Looney RI, Leary PC. Structural polymorphism of the human monocyte 40 kd Fc receptor for IgG. J Immunol 1987; 138: 2254-2256
    PubMedGoogle Scholar
  • 25 Looney RJ, Anderson CL, Ryan DH, Rosenfeld SI. Structural polymorphism in the human platelet Fcγ receptor. J Immunol 1988; 141: 2680-2683
    PubMedGoogle Scholar
  • 26 Tomiyama Y, Kunicki TJ, Zipf TF, Ford SB, Aster RH. Response of human platelets to activating monoclonal antibodies: importance of FcγRII (CD32) phenotype and level of expression. Blood 1992; 80: 2261-2268
    PubMedGoogle Scholar
  • 27 Parren PW H I, Warmerdam PA M, Boeije LC M, Capel PJ A, van de Winkle JG J, Aarden LA. Characterization of IgG FcR-mediated proliferation of human T cells induced by mouse and human anti-CD3 monoclonal antibodies. Identification of a functional polymorphism to human IgG2, anti- CTO J Immunol 1992; 148: 695-701
    PubMedGoogle Scholar
  • 28 Salmon JE, Edberg JC, Brogle NL, Kimberly RP. Allelic polymorphisms of human Fcγ Receptor IIA and Fcγ Receptor IIIB; independent mechanisms for differences in human phagocyte function. J Clin Invest 1992; 89: 1274-1281
    CrossrefPubMedGoogle Scholar
  • 29 Parren PW H I, Warmerdam PA M, Boeije LC M, Arts J, Westerdaal NA C, Vlug A, Capel PJ A, Aarden LA, van de Winkel JG J. On the interactions of IgG subclasses with the low affinity FcγRIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2 J Clin Invest 1992; 90: 1537-1546
    CrossrefPubMedGoogle Scholar
  • 30 Anderson GP, van de Winkle JG J, Anderson CL. Anti-GPIIb/IIIa (CD41) monoclonal antibody-induced platelet activation requires Fc receptordependentcell-cell interaction. Br J Haematol 1991; 79: 75-83
    CrossrefPubMedGoogle Scholar
  • 31 Marti GE, Magruder L, Schuette WE, Gralnick HR. Flow cytometric analysis of platelet surface antigens. Cytometry 1988; 9: 448-455
    CrossrefPubMedGoogle Scholar
  • 32 Gosselin EJ, Brown MF, Anderson CL, Zipf TF, Guyre PM. The monoclonal antibody 41H16 detects the Leu4 responder form of human FcγRII. J Immunol 1990; 144: 1817-1822
    PubMedGoogle Scholar
  • 33 Markwell MA K, Fox CF. Surface specific iodination of membrane proteins of viruses and eukaryotic cells using 1,3,4,6 tetrachloro 3,6 diphenylgly- colauril. Biochemistry 1978; 17: 4807-4817
    CrossrefPubMedGoogle Scholar
  • 34 Scatchard G. The attraction of proteins for small molecules and ions. Ann NY AcadSci 1949; 51: 660-672
    CrossrefPubMedGoogle Scholar
  • 35 Osborne JM, Chacko GW, Brandt JT, Anderson CL. Ethnic variation in frequency of an allelic polymorphism of human FcγRIIA determined with allele specific oligonucleotide probes. J Immunol Methods 1994; 173: 207-217
    CrossrefPubMedGoogle Scholar
  • 36 Bell GI, Karam JH, Rutter WJ. Polymorphic DNA region adjacent to the 5’ end of the human insulin gene. Proc Natl Acad Sci USA 1981; 78: 5759-5763
    CrossrefPubMedGoogle Scholar
  • 37 Anderson GP, Anderson CL. Signal transduction by the platelet Fc receptor. Blood 1990; 76: 1165-1172
    PubMedGoogle Scholar
  • 38 Horsewood P, Hayward CP M, Warkentin TE, Kelton JG. Investigation of the mechanisms of monoclonal antibody-induced platelet activation. Blood 1991; 78: 1019-1026
    PubMedGoogle Scholar
  • 39 Bredius RG M, de Vries CE E, Troelstra A, van Alphen L, Weening RS, van de Winkel JG J, Out TA. Phagocytosis of Staphylococcus aureus and Haemophilus influenzae type B opsonized with polyclonal human IgG1 and IgG2antibodies. Functional hFcγRIIa polymorphism to IgG2 J Immunol 1993; 151: 1463-1472
    PubMedGoogle Scholar
  • 40 Hulett MD, Witort E, Brinkworth RI, McKenzie IF C, Hogarth PM. Identification of the IgG binding site of the human low affinity receptor for IgG FcγRII. J Biol Chem 1994; 269: 15287-15293
    PubMedGoogle Scholar
  • 41 McCrae KR, Shattil SJ, Cines DB. Platelet activation induces increased Fcy receptor expression. J Immunol 1990; 144: 3920-3927
    PubMedGoogle Scholar
  • 42 Chong BH, Pilgrim RL, Cooley MA, Chesterman CN. Increased expression of platelet IgG Fc receptors in immune heparin-induced thrombocytopenia. Blood 1993; 81: 988-993
    PubMedGoogle Scholar
  • 43 Warkentin TE, Hayward CP M, Boshkov LK, Santos AV, Sheppard J-AI, Bode AP, Kelton JG. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity; an explanation for the thrombotic complications of heparin-induced ’ thrombocytopenia. Blood 1994; 84: 3691-3699
    CrossrefPubMedGoogle Scholar
  • 44 Boshkov LK, Warkentin TE, Hayward CP M, Andrew M, Kelton JG. Heparin-induced thrombocytopenia and thrombosis: clinical and laboratory studies. Br J Haematol 1993; 84: 322-328
    CrossrefPubMedGoogle Scholar
  • 45 Fijen CA P, Bredius RG M, Kuijper EJ. Polymorphism of IgG Fc receptors in meningococcal disease: risk marker in complement deficient patients. Ann Intern Med 1993; 119: 636
    PubMedGoogle Scholar
  • 46 Bredius RG M, Derkx BH F, Fijen CA P, de Wit TP M, de Haas M, Weening RS, van de Winkel JG J, Out TA. Fcy receptor Ha (CD32) polymorphism in fulminant meningococcal septic shock in children. J Infect Dis 1994; 170: 848-853
    CrossrefPubMedGoogle Scholar
  • 47 Sanders EA, van de Winkel JG J, Feldman RG, Voorhorst-Ogink MM, Rijkers GT, Capel PJ A, Zegers BJ. Fc gamma IIA receptor phenotype and opsonophagocytosis in two patients with recurrent bacterial infections. Immunodeficiency 1993; 4: 163-165
    PubMedGoogle Scholar
  • 48 Gmella-Meyling FH J, Bootsma H, Derksen RH W M, Spronk PE, Kater L, Kallenberg CG M, Capel PJ A, van de Winkle JG J, Duits AJ. IgG Fc receptor Ha (CD32) polymorphism in SLE: skewed allotype distribution among patients with renal disease. Arthr Rheumat 1994; 37 (Suppl) S167 (abstract)
    PubMedGoogle Scholar
  • 49 Blasini AM, Stekman IL, Leon-Ponte M, Caldera D, Rodriguez MA. Increased proportion of responders to a murine anti-CD3 monoclonal antibody of the IgG1class in patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 1993; 94: 423-428
    PubMedGoogle Scholar
  • 50 Salmon JE, Millard SS, Arnett FC, Ramsey-Goldman R, McKenzie S, Reilly A, Kimberly RP. FcγRIIa is a non-MHC heritable risk factor for SLE in African-Americans. Arthr Rheumat 1994; 37 (Suppl) S167 (abstract)
    PubMedGoogle Scholar